George D. Demetri and others from the American Dana Fabre / Briegen and Women ‘s Hospital Cancer Center reported that among patients with liposarcoma, the use of iriprine in the back-line treatment had significantly improved survival advantages over dacarbazine. For patients with liposarcoma, the most important thing is to choose iribrin treatment, because the pathological type of the disease has a limited effect on the efficacy. (J Clin Oncol. Online version August 30, 2017)
A previous phase III clinical trial showed that irribrin compared to dacarbazine in the treatment of advanced liposarcoma or leiomyosarcoma can significantly improve overall survival (OS), and the adverse reactions are easy to manage and control. Now the researchers conducted a subgroup analysis of the situation of the iribulin group and the dacarbazine group, with the aim of clarifying the relevant tissue specificity and safety.
Enrollment conditions: patient age ≥18 years; advanced or advanced liposarcoma that cannot be cured by surgery or radiotherapy; ECOG performance status score ≤2; previous chemotherapy regimens ≥2, including anthracycline. Patients were randomly divided into erebrin group (1.4 mg / m2, d1, 8) or dacarbazine group (850 mg / m2, 1000 mg / m2, or 1200 mg / m2, d1) in a 1: 1 ratio. 21 days is a cycle. Study endpoints include OS, progression-free survival (PFS), and safety.
The results showed that the OS in the liposarcoma subgroup was significantly improved. The median OS in the iribulin and dacarbazine groups was 15.6 months and 8.4 months, respectively (HR = 0.51, 95% CI 0.35 ~ 0.75 ; P <001). In the iribulin group, patients with liposarcoma of all histological subtypes and patients in all regions achieved OS improvement. The median PFS of patients in the erebrin group was 2.9 months and 1.7 months relative to the dacarbazine group (HR = 0.52, 95% CI 0.35 ~ 0.78; P = 0.0015). Adverse events were similar between the two groups.
